BLK and chronic myelogenous leukemia, BCR-ABL1 positive: Although a nascent body of evidence suggests BLK may be a useful biomarker and drug target in solid human malignancies, BLK activity is context dependent and acts as a tumor suppressor in chronic myeloid leukemia [50,51].